Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immunocore (IMCR) to $37 from $36 and keeps a Neutral rating on the shares following the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
- Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
- Immunocore Reports Strong Growth in Q3 2025
- Immunocore reports Q3 EPS 0c, consensus (24c)
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls